Cat 2 — reviewLongevity

Epitalon

Epithalamin / Tetrapeptide AEDG

Pineal gland-derived tetrapeptide studied for telomere lengthening via telomerase activation. 40+ years of Russian research by Dr. Vladimir Khavinson. Under FDA review for Category 1 status.

Evidence

Human data exists

Routes

injectable, nasal

Available since

Developed by Vladimir Khavinson in Russia in the 1980s. Western research access and interest from approximately 2010s onward.

Mechanism of action

Activates telomerase — the enzyme that extends telomeres, the protective caps on chromosomes that shorten with each cell division and aging. Also regulates melatonin production and circadian gene expression. Reduces oxidative stress markers in animal models.

Effects in the body

Epitalon's primary research interest is in telomere biology — one of the most credible mechanistic pathways in aging science. Telomeres shorten with age, and short telomeres are associated with cellular aging. Khavinson published over 40 years of research on this peptide.

Pros & cons (from the literature)

Pros

Telomerase activation is a real, scientifically documented mechanism
40+ years of Russian clinical research data from Khavinson
Melatonin-regulating effects studied for sleep improvement
Strong antioxidant effects demonstrated in animal models
Theoretical cancer-suppression via telomere stability

Cautions

Telomerase activation also promotes cancer cell survival — serious theoretical dual-use concern
Western human clinical data essentially absent
Most evidence comes from Russian literature not independently peer-reviewed in Western journals
No established human dosing protocol in Western medicine
Currently Category 2 — cannot be legally compounded in USA

Protocol summary (from published research)

Khavinson protocol used in Russian research: 5–10 mg per day for 10–20 day cycles, repeated twice per year. Subcutaneous or intramuscular injection. Some nasal spray formulations also used in Russian clinical practice.

Dosing ranges reproduced from published research literature. Not a prescription, not medical advice.

FDA & regulatory status

Category 2 status — scheduled for PCAC review at July 23-24 2026 hearing. Cannot currently be compounded by licensed US pharmacies. Available only through research use only (RUO) channels currently.

Evidence base

Khavinson V.Kh. published extensively in Russian and some international literature. Mechanistically credible telomerase activation. Independent Western validation needed for broader acceptance.

Primary research sources

Peer-reviewed literature referenced throughout this profile is drawn from PubMed, Cell Metabolism, and clinical trial registries cited in the evidence base above.

Expert perspective — Dr. Alex Tatem, Urologist

Dr. Alex Tatem is a board-certified Urologist and Men's Health Specialist who has studied peptides for 12 years. Videos featured for educational purposes. ThePeptide.expert is an independent platform.

Dr. Tatem discusses Epitalon as part of the peptides currently under FDA review for Category 1 reclassification.

Important. ThePeptide.expert summarizes published research. We are not a pharmacy, do not prescribe, and make no therapeutic claims. Regulatory status varies by jurisdiction.